Psilocybin clinical trials at UCSF
4 in progress, 2 open to eligible people
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
open to eligible people ages 40-75
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
San Francisco, California
Psilocybin Therapy for Depression in Bipolar II Disorder
open to eligible people ages 30-65
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.
San Francisco, California
Comparing the Effects of Psilocin and Psilocybin in Healthy Adults
Sorry, not yet accepting patients
To compare the physiological and psychological effects of psilocin taken orally by pill or sublingually by dissolving a tablet under the tongue to those of psilocybin taken by pill in healthy adults.
Psilocybin Therapy for Chronic Low Back Pain
Sorry, not yet accepting patients
This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur at UCSF. Each participant will receive a dose of psilocybin with possibly one or more other drugs. Participants will undergo two preparation sessions, a dosing session, three integration sessions to discuss their psilocybin experience, and several follow up sessions.
Our lead scientists for Psilocybin medical studies include Joshua Woolley, MD/PhD Jacob Aday.
Last updated: